| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H23N3O |
| Molecular Weight | 285.384 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC1CCC(CC1)C2=NC(=NO2)C3=CC=NC=C3
InChI
InChIKey=OAVLEYPTWABFLF-UHFFFAOYSA-N
InChI=1S/C17H23N3O/c1-2-3-4-13-5-7-15(8-6-13)17-19-16(20-21-17)14-9-11-18-12-10-14/h9-13,15H,2-8H2,1H3
| Molecular Formula | C17H23N3O |
| Molecular Weight | 285.384 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 8.4 µM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Sample Use Guides
In the model of insuline resistance, PSN375963 was administered to mice by intraperitoneal injection in combination with glucose. Dose of 0.1 umol/l/kg did not lead to statistically significant difference in AUC of plasma insulin.
Route of Administration:
Intraperitoneal
